UNSPSC 51373006: Pentazocine hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C19H27NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A36BXO4PPX, chemically known as 2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, hydrochloride, (2r,6r,11r)-rel- but more generally known as pentazocine hydrochloride, which bears US NIH Compound Identifier 107799.

UNSPSC 51373006 Pentazocine hydrochloride is a Commodity code that nominally describes a specific opioid analgesic, but recent state and local procurement activity under this code focuses on pharmaceutical distribution, naloxone procurement, and generic drug supply agreements rather than pentazocine specifically. State and local governments use this code—or codes near it in the pharmaceutical taxonomy—to solicit pharmaceuticals, over-the-counter products, and drug-related health and safety items through health departments, cooperative purchasing alliances, and community health agencies. The issuing bodies are diverse: county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and other participating jurisdictions). The scope of work spans both direct pharmaceutical procurement and exploration of alternative pharmacy delivery models, including direct-to-manufacturer prescription programs designed to improve cost management and fulfillment efficiency outside traditional pharmacy benefit manager and group purchasing organization channels.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon, with broader multistate reach through cooperative purchasing vehicles. Recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription capabilities; and the Minnesota Department of Administration's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) under MMCAP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with contract effectiveness July 1, 2026. The MMCAP procurement emphasizes cGMP and Drug Supply Chain Security Act compliance, pricing flexibility across multiple formats, and performance penalties for late reporting or missed onboarding timelines. Note that the Seminole County opportunity shows a due date of July 26, 2023, which appears to be a historical record despite the June 2026 posting date.